GLP-1 Stopping & Quitting Statistics (2026): The Emotional & Physical Experience

Most cited

Cost-related barriers — including monthly out-of-pocket expense, insurance non-coverage, and prior authorization denials — are the most commonly cited reason for GLP-1 discontinuation in published surveys

KFF tracking data consistently shows that affordability is the top concern for GLP-1 users. Cost-related discontinuation affects all income levels but disproportionately affects uninsured and underinsured individuals.

Common reason

Side effects — particularly persistent nausea, gastrointestinal distress, and fatigue — are frequently cited as a reason for GLP-1 discontinuation

Side effects are reported as the second most common reason for stopping after cost. The STEP 1 trial reported that gastrointestinal events were the most common adverse events, though most were mild to moderate.

6–12 months

is the average time to peak weight regain after stopping GLP-1 medications, according to published clinical data

The STEP 1 extension trial and subsequent analyses indicate that weight regain typically accelerates in the first 6 months after discontinuation and plateaus by approximately 12 months, at which point most participants had regained a substantial portion of their lost weight.

Poorly quantified

The proportion of individuals who maintain significant weight loss long-term after stopping GLP-1 therapy remains poorly quantified in published literature

Most published data focuses on the first year after discontinuation. Longer-term outcomes (2+ years) have not been rigorously studied. Individual results vary significantly based on lifestyle changes implemented during treatment.

Brief

Published research indicates that metabolic changes from GLP-1 therapy persist only briefly after discontinuation

Improvements in insulin sensitivity, appetite regulation, and metabolic markers observed during GLP-1 therapy tend to diminish within weeks to months after stopping. This supports the clinical rationale for long-term or indefinite use in patients with obesity.

~15%

average body weight loss achieved in the STEP 1 trial before discontinuation, providing the baseline against which regain is measured

The STEP 1 trial enrolled adults with overweight or obesity (BMI ≥30, or ≥27 with at least one weight-related comorbidity) and demonstrated significant weight loss with semaglutide 2.4 mg weekly over 68 weeks.

Top barrier

Adults surveyed by KFF who had considered or used GLP-1 medications consistently identified cost as a major barrier to starting or continuing treatment

The KFF Health Tracking Poll has consistently found that cost is the single most significant factor influencing GLP-1 access and persistence, particularly for individuals without comprehensive insurance coverage.

Chronic

Leading medical organizations increasingly classify obesity as a chronic disease requiring ongoing treatment, analogous to hypertension or diabetes management

This framing supports the clinical recommendation that GLP-1 therapy may need to be continued long-term or indefinitely, rather than used as a short-term intervention — a position that has significant implications for insurance coverage and patient expectations.